CROI 2015 Program and Abstracts

Oral Sessions

Session O-13 Oral Abstracts

Room 6D

147 High SVR Regardless of Time to SuppressionWith ABT-450/r/Ombitasvir and Dasabuvir+RBV DavidWyles 1 ; Joseph J. Eron 2 ; RogerTrinh 3 ; Jay Lalezari 4 ; ChiaWang 5 ; Laveeza Bhatti 6 ; Peter Gulick 7 ; Barbara McGovern 3 ; Linda Fredrick 3 ; Mark Sulkowski 8 1 University of California San Diego, La Jolla, CA, US; 2 University of North Carolina, Chapel Hill, NC, US; 3 Abbvie Inc, North Chicago, IL, US; 4 Quest Clinical Research, San Francisco, CA, US; 5 Virginia Mason Medical Center, Seattle, WA, US; 6 AIDS Healthcare Foundation, Los Angeles, CA, US; 7 Michigan State University, East Lansing, MI, US; 8 Johns Hopkins University, Baltimore, MD, US 148 The Paradox of Highly Effective Sofosbuvir Combo Therapy Despite Slow Viral Decline Thi HuyenTram Nguyen 1 ; Jérémie Guedj 1 ; Laetitia Canini 2 ; Anu Osinusi 5 ; Phillip S. Pang 5 ; John McHutchison 5 ; Henry Masur 6 ; Anita Kohli 3 ; Shyam Kottilil 4 ; Alan S Perelson 2 1 IAME, UMR 1137, Inserm, F-75018 Paris, France; Univ Paris Diderot, Sorbonne Paris Cité, F-75018 Paris, France, Paris, France; 2 Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, US; 3 Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Frederick, MD, US; 4 Laboratory of Immunoregulation, NIAID, NIH, Bethesda, MD, US; 5 Gilead Sciences, Inc, Foster City, MD, US; 6 NIH Clinical Center, Bethesda, MD, US 149 Real-World Pharmaceutical Costs in the Simeprevir/Sofosbuvir Era: $164,485 per SVR4 Kian Bichoupan 1 ; NeetaTandon 2 ; RachanaYalamanchili 1 ; Neal M. Patel 1 ; Sweta Chekuri 1 ; Alyson Harty 1 ;Thomas Schiano 1 ; PonniV. Perumalswami 1 ; Douglas Dieterich 1 ; Andrea D. Branch 1 1 Mount Sinai School of Medicine, New York, NY, US; 2 Janssen Scientific Affairs, Titusville, NJ, US 150 Impact of Deferring HCV Treatment on Liver-Related Events in HIV+ Patients Cindy Zahnd 1 ; Luisa P. Salazar-Vizcaya 1 ; Jean-François Dufour 2 ; Beat Müllhaupt 3 ; Gilles Wandeler 1 ; Roger Kouyos 3 ; Barbara Bertisch 1 ; Andri Rauch 2 ; Olivia Keiser 1 On behalf of the Swiss HIV and Hepatitis C Cohort Studies 1 Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; 2 University Hospital Bern, Bern, Switzerland; 3 University Hospital Zurich, Zurich, Switzerland 151LB Daclatasvir in CombinationWith Sofosbuvir for HIV/HCV Coinfection: ALLY-2 Study DavidWyles 1 ; Peter Ruane 2 ; Mark Sulkowski 3 ; Douglas Dieterich 4 ; Anne Luetkemeyer 5 ; Timothy Morgan 6 ; Kenneth E. Sherman 7 ; Zhaohui Liu 8 ; Stephanie Noviello 8 ; Peter Ackerman 8 1 University of California San Diego, La Jolla, CA, US; 2 Ruane Medical and Liver Health Institute, Los Angeles, CA, US; 3 Johns Hopkins University School of Medicine, Baltimore, MD, US; 4 Icahn School of Medicine at Mount Sinai, New York, NY, US; 5 University of California and San Francisco General Hospital, San Francisco, CA, US; 6 VA Long Beach Healthcare System, Long Beach, CA, US; 7 University of Cincinnati College of Medicine, Cincinnati, OH, US; 8 Bristol-Myers Squibb Co, Princeton, NJ, US 152LB Ledipasvir/Sofosbuvir for 12Weeks in Patients CoinfectedWith HCV and HIV-1 Susanna Naggie 1 ; Curtis Cooper 2 ; Michael S. Saag 3 ; Jenny C.Yang 4 ; Luisa M. Stamm 4 ; Phillip S. Pang 4 ; John McHutchison 4 ; Douglas Dieterich 5 ; Mark Sulkowski 6 On behalf of the ION-4 StudyTeam 1 Duke Clinical Research Institute, Durham, NC, US; 2 University of Ottawa, Ottawa, Canada; 3 University of Alabama at Birmingham, Birmingham, AL, US; 4 Gilead Sciences, Inc, Foster City, CA, US; 5 Mount Sinai Health System, New York, NY, US; 6 Johns Hopkins University School of Medicine, Baltimore, MD, US

10:00 am– 12:15 pm Reaching Populations: Demonstrating Impact Moderators Sarah Fidler , Imperial College and Imperial College NHS Trust, London, United Kingdom Jessica E. Justman , Columbia University Medical Center, New York, NY, US 153 Population Viral Load in Three High HIV Prevalence Settings in Sub- Saharan Africa David Maman 1 ; Helena Huerga 1 ; GillesVan Cutsem 2 ; Irene Mukui 3 ; Benson Chilima 4 ; Beatrice Kirubi 5 ; Ruggero G. Giuliani 2 ; Elisabeth Szumilin 6 ; Charles Masiku 7 ; Jean-François Etard 1 1 Epicentre/Médecins Sans Frontières, Paris, France; 2 Médecins Sans Frontières, Cape Town, South Africa; 3 National AIDS and STDs Control Program, Nairobi, Kenya; 4 Ministry of Health, Lilongwe, Malawi; 5 Médecins Sans Frontières, Nairobi, Kenya; 6 Médecins Sans Frontières, Paris, France; 7 Médecins Sans Frontières, Lilongwe, Malawi Simbarashe Takuva 1 ; Alison Brown 2 ;WilliamMacleod 3 ;Yogan Pillay 4 ;Valerie Delpech 2 ; Adrian J. Puren 1 1 National Institute for Communicable Diseases, NHLS, Johannesburg, South Africa; 2 Centre for Infectious Diseases Surveillance, Public Health England, London, United Kingdom; 3 Boston University, Boston, MA, US; 4 National Department of Health, Pretoria, South Africa 155 Decentralizing Access to Antiretroviral Therapy Services for Adults in Swaziland Andrew F. Auld 1 ; Harrison Kamiru 2 ; Charles Azih 3 ; Andrew L. Baughman 1 ; Harriet Nuwagaba-Biribonwoha 2 ; Peter Ehrenkranz 1 ; Simon Agolory 1 ;TeddV. Ellerbrock 1 ;Velephi Okello 3 ; George Bicego 1 1 US Centers for Disease Control and Prevention, Atlanta, GA, US; 2 ICAP, Columbia University, New York, NY, US; 3 Ministry of Health, Mbabane, Swaziland 156 Who Are the 10-Year AIDS Survivors on Antiretroviral Therapy in Haiti? Samuel Pierre 1 ; Ashita Batavia 2 ; Patrice Severe 1 ;Vanessa Rouzier 1 ; Benedict Charles 1 ; Jean Pape 1 ;Warren Johnson 2 ; Daniel Fitzgerald 2 ; Margaret L. McNairy 2 On behalf of Les Centres GHESKIO CTU 1 Les Centres GHESKIO, Port-au-Prince, Haiti; 2 Weill Cornell Medical College, New York, NY, US 157 Nationwide Evaluation of Antiretroviral Therapy Coverage on Prevention in Rwanda: A Multisectional Time-Trend Analysis Sabin Nsanzimana 2 ; Eric Remera 2 ; Steve Kanters 1 ; Eric Dusabe 2 ; Adeline Dukuze 2 ;Till 1 Stanford University, Vancouver, Canada; 2 Rwanda Biomedical Centre, Kigali, Rwanda; 3 Harvard School of Public Health, Boston, MA, US; 4 BC Centre for Excellence in HIV/AIDS, Vancouver, Canada 158 Impact of Male Circumcision Scale-Up on Community-Level HIV Incidence in Rakai, Uganda Xiangrong Kong 1 ; Godfrey Kigozi 2 ; Fred Nalugoda 2 ; David Serwadda 3 ; Maria J.Wawer 1 ; Ronald H. Gray 1 On behalf of the Rakai Health Sciences Program 1 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 2 Rakai Health Sciences Program, Entebbe, Uganda; 3 Makerere University College of Health Sciences, Kampala, Uganda 159 Effects of Antiretroviral Treatment on Health Care Utilization in Rural South Africa Jan A. Hontelez 1 ; FrankTanser 2 ; Sake J. deVlas 1 ; Kevindra K. Naidu 2 ; Rob Baltussen 3 ; Deenan Pillay 2 ;Till Barnighausen 2 1 Erasmus University Medical Center, Nijmegen, Netherlands; 2 Africa Centre for Health and Population Studies, Somkhele, South Africa; 3 Radboud University Medical Centre, Nijmegen, Netherlands 160 The Impact of PEPFAR Abstinence and Faithfulness Funding Upon HIV Risk Behaviors in Sub-Saharan Africa Nathan C. Lo ; Anita Lowe; Eran Bendavid Stanford University School of Medicine, Stanford, CA, US Barnighausen 3 ; Eran Bendavid 1 ; Julio Montaner 4 ; Edward Mills 1 On behalf of the RwandaTreatment as PreventionWorking Group 154 Disparities in Engagement Within HIV Care in South Africa

Thursday, February 26, 2015 • Oral Sessions

17

CROI 2015